Historical epidemiology of hepatitis C virus (HCV) in selected countries
…, H Wedemeyer, N Weis, J Wiegand… - Journal of viral …, 2014 - Wiley Online Library
Chronic infection with hepatitis C virus (HCV) is a leading indicator for liver disease. New
treatment options are becoming available, and there is a need to characterize the …
treatment options are becoming available, and there is a need to characterize the …
[HTML][HTML] The etiology, diagnosis and prevention of liver cirrhosis: part 1 of a series on liver cirrhosis
J Wiegand, T Berg - Deutsches Ärzteblatt International, 2013 - ncbi.nlm.nih.gov
… Wiegand has served as a paid consultant for Gilead. He has received reimbursement of
congress participation fees and travel and accommodation expenses, as well as payment for the …
congress participation fees and travel and accommodation expenses, as well as payment for the …
[HTML][HTML] Acute hepatitis C: current status and remaining challenges
T Santantonio, J Wiegand, JT Gerlach - Journal of hepatology, 2008 - Elsevier
The acute phase of hepatitis C virus (HCV) infection represents a key point in the evolution
of hepatitis C. In some patients, the infection resolves spontaneously, whereas in others it …
of hepatitis C. In some patients, the infection resolves spontaneously, whereas in others it …
Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis
…, J Bojunga, P Bedossa, V Keim, J Wiegand - Journal of …, 2017 - Elsevier
Background & Aims The prevalence of fatty liver underscores the need for non-invasive
characterization of steatosis, such as the ultrasound based controlled attenuation parameter (…
characterization of steatosis, such as the ultrasound based controlled attenuation parameter (…
The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm
…, H Wedemeyer, N Weis, J Wiegand… - Journal of viral …, 2014 - Wiley Online Library
The disease burden of hepatitis C virus ( HCV ) is expected to increase as the infected population
ages. A modelling approach was used to estimate the total number of viremic infections…
ages. A modelling approach was used to estimate the total number of viremic infections…
Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis
Objective Liver biopsy is still needed for fibrosis staging in many patients with non-alcoholic
fatty liver disease. The aims of this study were to evaluate the individual diagnostic …
fatty liver disease. The aims of this study were to evaluate the individual diagnostic …
A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice
…, Y Lokhnygina, U Kullig, U Göbel, E Capka, J Wiegand… - Gastroenterology, 2010 - Elsevier
BACKGROUND & AIMS:: A single nucleotide polymorphism (SNP) upstream of the IL28B
gene has been associated with response of patients with chronic hepatitis C to therapy with …
gene has been associated with response of patients with chronic hepatitis C to therapy with …
A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity
B-cell lymphoma extra large (BCL-X L ) is a well-validated cancer target. However, the on-target
and dose-limiting thrombocytopenia limits the use of BCL-X L inhibitors, such as ABT263…
and dose-limiting thrombocytopenia limits the use of BCL-X L inhibitors, such as ABT263…
Strategies to manage hepatitis C virus (HCV) disease burden
The number of hepatitis C virus ( HCV ) infections is projected to decline while those with
advanced liver disease will increase. A modeling approach was used to forecast two treatment …
advanced liver disease will increase. A modeling approach was used to forecast two treatment …
Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis
…, H Garg, O Chazouillères, J Wiegand… - The Lancet …, 2021 - thelancet.com
Background Diagnostic tools for liver disease can now include estimation of the grade of
hepatic steatosis (S0 to S3). Controlled attenuation parameter (CAP) is a non-invasive method …
hepatic steatosis (S0 to S3). Controlled attenuation parameter (CAP) is a non-invasive method …